Ripretinib
- Generic Name
- Ripretinib
- Brand Names
- Qinlock
- Drug Type
- Small Molecule
- Chemical Formula
- C24H21BrFN5O2
- CAS Number
- 1442472-39-0
- Unique Ingredient Identifier
- 9XW757O13D
- Background
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.
...
- Indication
Ripretinib is indicated to treat adults diagnosed with advanced gastrointestinal stromal tumor (GIST) who have had prior therapy with at least 3 kinase inhibitors, including with imatinib.
- Associated Conditions
- Advanced Gastrointestinal Stromal Tumor (GIST)
- Associated Therapies
- -
Ripretinib (QINLOCK®) According to Current SmPC
- Conditions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 100
- Registration Number
- NCT06619275
- Locations
- 🇩🇪
Praxis für interdisziplinäre Onkologie und Hämatologie, Freiburg, Germany
A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 94
- Registration Number
- NCT05957367
- Locations
- 🇺🇸
University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT05734105
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇨🇦Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
- Conditions
- Interventions
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Registration Number
- NCT05080621
A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
- Conditions
- Interventions
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT04633122
- Locations
- 🇨🇳
The 4th Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳The Cancer Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST
- Conditions
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT04530981
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
- Conditions
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Registration Number
- NCT04148092
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 453
- Registration Number
- NCT03673501
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
🇺🇸UCLA Hematology Oncology Center - Main Site, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.